

Hanoi, May 14, 2025

**PROPOSAL**

**Re: Approval of Profit Distribution Plan**

- Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17, 2020, and the amended and supplemented Law No. 03/2022/QH15 dated January 11, 2022;
- Pursuant to the Law on Securities No. 54/2019/QH14 dated November 26, 2019, and Law No. 56/2024/QH15 dated November 29, 2024, which amends and supplements certain provisions of Law No. 54/2019/QH14;
- Pursuant to the Charter of Organization and Operation of Central Pharmaceutical Joint Stock Company No.1 – Pharbaco;
- Pursuant to the audited consolidated financial statements for the fiscal year 2025, prepared by iCPA International Auditing Co., Ltd. on March 30, 2026;


The Board of Directors of Central Pharmaceutical Joint Stock Company No.1 – Pharbaco hereby submits to the General Meeting of Shareholders for approval the following **profit distribution plan for 2025**:

No.	Description	Amount (VND)
1	Undistributed after-tax profit per the parent company's 2025 financial statements	31.505.675.841
2	Retained earnings carried forward from previous years	30.875.760.141
3	Accumulated distributable profit as of December 31, 2024	62.381.435.982
4	Proposed distribution of profit:	35.009.534.400
	- Dividend distribution (in shares) / Owner's equity	3%
5	Retained earnings after distribution	27.371.901.582

(Source: Audited Financial Statements for 2025)

We respectfully submit to the General Meeting of Shareholders for consideration and approval.

ON BEHALF OF THE BOARD OF DIRECTORS  
CHAIRMAN



To Thanh Hung